About this Journal Submit a Manuscript Table of Contents
Journal of Oncology
Volume 2010 (2010), Article ID 919620, 17 pages
http://dx.doi.org/10.1155/2010/919620
Review Article

Current and Future Trends in Magnetic Resonance Imaging Assessments of the Response of Breast Tumors to Neoadjuvant Chemotherapy

1Department of Radiology and Radiological Sciences, Institute of Imaging Science, Nashville, TN 37232-2310, USA
2Department of Biomedical Informatics, Institute of Imaging Science, Nashville, TN 37232-2310, USA
3Department of Medicine, Institute of Imaging Science, Nashville, TN 37232-2310, USA
4Department of Biomedical Engineering, Institute of Imaging Science, Nashville, TN 37232-2310, USA
5Department of Physics and Astronomy, Institute of Imaging Science, Nashville, TN 37232-2310, USA
6Department of Molecular Physiology and Biophysics, Institute of Imaging Science, Nashville, TN 37232-2310, USA
7Department of Cancer Biology, Institute of Imaging Science, Nashville, TN 37232-2310, USA

Received 28 April 2010; Revised 7 July 2010; Accepted 11 August 2010

Academic Editor: Massimo Aglietta

Copyright © 2010 Lori R. Arlinghaus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The current state-of-the-art assessment of treatment response in breast cancer is based on the response evaluation criteria in solid tumors (RECIST). RECIST reports on changes in gross morphology and divides response into one of four categories. In this paper we highlight how dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted MRI (DW-MRI) may be able to offer earlier, and more precise, information on treatment response in the neoadjuvant setting than RECIST. We then describe how longitudinal registration of breast images and the incorporation of intelligent bioinformatics approaches with imaging data have the potential to increase the sensitivity of assessing treatment response. We conclude with a discussion of the potential benefits of breast MRI at the higher field strength of 3T. For each of these areas, we provide a review, illustrative examples from clinical trials, and offer insights into future research directions.